dokumendiregister.ee
Väljaminev kiriAvalik

Vastused küsimustele

Ravimiamet · 16. juuli 2024
Viit
JUH-8/2579-2
Registreeritud
16. juuli 2024
Dokumendi liik
Väljaminev kiri
Adressaat
Thomson Reuters Corporation
Saabumis/saatmisviis
Outlook
Funktsioon
JUH Juhtimine
Sari
JUH-8 Kirjavahetus pressiga
Toimik
JUH-8/2024
Vastutaja
Carmen Katariina Sikk (RA)

Failid

Sisu (failidest)

Saatja: "Carmen Katariina Sikk" <[email protected]> Saaja: "Kärolin Jenas" <[email protected]> Teema: Ed: Journalist query - semaglutide Kuupäev: 2024-07-03 06:29 Saatja: Carmen Katariina Sikk Saatmisaeg: kolmapäev, 3. juuli 2024 09:28 Adressaat: 'Silver, Andrew (Reuters)' <[email protected]> Teema: Vs: Journalist query - semaglutide Hello, Andrew! Aet Viispert (head of the department of marketing authorisations) answered: Determination of whether the patent is applicable is the responsibility of the applicant/marketing authorisation holder. During the term of protection of the patent or SPC of the reference medicinal product, there can be no commercial use of the resulting final medicinal products obtained for the purposes of the regulatory approval process. The competent authorities responsible for the authorisation of medicines cannot assess the marketing authorisation applications and make decisions based on the patent or SPC status of the reference medicinal product. Carmen Katariina Sikk Agency of Medicines Head of Communications Tel 737 4140 [email protected] <mailto:[email protected]> Saatja: Silver, Andrew (Reuters) <[email protected] <mailto:[email protected]> > Saatmisaeg: esmaspäev, 1. juuli 2024 18:19 Adressaat: Carmen Katariina Sikk <[email protected] <mailto:[email protected]> > Teema: Journalist query - semaglutide Hi I’m a journalist with Reuters in Shanghai, I write about health and pharma. I’ve heard there may be some countries where there is no patent on semaglutide. Do you know if any companies in those countries are producing oral pill or injectible versions of semaglutide drugs (i.e. rybelsus generic/biosimilar) for consumers that are sold to people based in countries with patent protection (i.e. directly or via third-party distributors) like Estonia, and are there any examples you can share? Or how common such a phenomenon is, what countries are involved? Appreciate your time, -Andrew
Allikas: Ravimiamet dokumendiregister →